Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-10-17
    E.g., 2018-10-17

Archive Search

9 results
1:41 PM, Oct 05, 2018  |  BC Week In Review | Company News  |  Other News

Momenta cutting biosimilar programs, headcount

Momenta Pharmaceuticals Inc. (NASDAQ:MNTA) said it plans to terminate five biosimilar development programs under its 2016 co-development deal with Mylan N.V. (NASDAQ:MYL) and reduce headcount by about 50% to focus on its novel pipeline. The...
7:50 AM, Apr 06, 2018  |  BC Week In Review | Company News  |  Other News

Samsung Bioepis, AbbVie settle Humira biosimilar dispute

in 2016. In March, the EC approved ABP 501 under two names: Amgevita and Solymbic. Kyowa Hakko Kirin
12:00 AM, Jan 19, 2015  |  BC Week In Review | Company News  |  Other News

Aveo Pharmaceuticals cancer news

has exclusive ex-Asian rights to the inhibitor of VEGF receptors 1, 2 and 3 from Kyowa Hakko Kirin
12:00 AM, Sep 16, 2013  |  BC Week In Review | Company News  |  Other News

Kyowa Hakko Kirin, Cancer Science Institute of Singapore, National University Cancer Institute, National University of Singapore cancer news

Kyowa's Kyowa Hakko Kirin Pte. Ltd. Singaporean subsidiary established its Singapore Translational Research Laboratory (STRL), an R&D center …
discovered by Kyowa and evaluate biomarker candidates. The partners could not be reached for details. Kyowa Hakko Kirin
12:00 AM, Jul 22, 2013  |  BC Week In Review | Company News  |  Other News

Aveo Pharmaceuticals cancer news

has exclusive ex-Asian rights to the inhibitor of VEGF receptors 1, 2 and 3 from Kyowa Hakko Kirin
12:00 AM, Jun 10, 2013  |  BC Week In Review | Company News  |  Other News

Aveo Pharmaceuticals cancer news

has exclusive, ex-Asian rights to the inhibitor of VEGF receptors 1, 2 and 3 from Kyowa Hakko Kirin
12:00 AM, Nov 05, 2012  |  BC Week In Review | Company News  |  Other News

Aveo Pharmaceuticals cancer news

has exclusive ex-Asian rights to the inhibitor of VEGF receptors 1, 2 and 3 from Kyowa Hakko Kirin
12:00 AM, Oct 15, 2012  |  BC Week In Review | Company News  |  Other News

Orexo neurology news

pain drug Abstral fentanyl, effective Jan. 1, 2013, from the ProStrakan Group plc subsidiary of Kyowa Hakko Kirin
12:00 AM, Feb 27, 2012  |  BC Week In Review | Company News  |  Other News

Aveo Pharmaceuticals, Astellas cancer news

of VEGF receptors 1, 2 and 3. Aveo has exclusive ex-Asian rights to tivozanib from Kyowa Hakko Kirin